test-1 | OncLive

pdated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study. Women’s use of facial skin care products saw a significant rise in 2020 due to the COVID-19 pandemic, according to The NPD Group, a market research company. itthikorn / stock.adobe.com Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum. Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category. It’s no secret that veterinary professionals are resilient. During the COVID-19 pandemic, the profession was confronted with significant challenges but adjusted to sudden, drastic changes and propelled forward to meet the new and growing demands. “Our profession is resilient, and if our profession is resilient, that means the professionals within the profession are resilient,” said Kara Burns, MS, MEd, LVT, VTS (Nutrition). “If we’re resilient it means we [have] recovered from [things] and learned to change course and move forward.” When faced with adversity because of a worldwide pandemic or a challenging situation in the clinic—having the right tools to help you maintain resiliency is crucial. During her talk during the 2021 vi Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field. For decades, the standard of care has been a platinum doublet, either cisplatin or carboplatin with etoposide. However, progress has not moved much beyond that, explains Mansfield. Although these regimens are fairly effective in terms of tumor shrinkage, the responses have not been durable. After initial response, the tumor tends to progress quickly thereafter. Patients with a diagnosis of SCLC have poor survival, averages of which have yet to surpass 1 year. Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field. For decades, the standard of care has been a platinum doublet, either cisplatin or carboplatin with etoposide. However, progress has not moved much beyond that, explains Mansfield. Although these regimens are fairly effective in terms of tumor shrinkage, the responses have not been durable. After initial response, the tumor tends to progress quickly thereafter. Patients with a diagnosis of SCLC have poor survival, averages of which have yet to surpass 1 year. Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field. For decades, the standard of care has been a platinum doublet, either cisplatin or carboplatin with etoposide. However, progress has not moved much beyond that, explains Mansfield. Although these regimens are fairly effective in terms of tumor shrinkage, the responses have not been durable. After initial response, the tumor tends to progress quickly thereafter. Patients with a diagnosis of SCLC have poor survival, averages of which have yet to surpass 1 year. Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field. For decades, the standard of care has been a platinum doublet, either cisplatin or carboplatin with etoposide. However, progress has not moved much beyond that, explains Mansfield. Although these regimens are fairly effective in terms of tumor shrinkage, the responses have not been durable. After initial response, the tumor tends to progress quickly thereafter. Patients with a diagnosis of SCLC have poor survival, averages of which have yet to surpass 1 year.